Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study.

Authors
Mohan, Divya 
Forman, Julia R 
Allinder, Matthew 
McEniery, Carmel M 
Bolton, Charlotte Emma 

No Thumbnail Available
Type
Article
Change log
Abstract

Cardiovascular and skeletal muscle manifestations constitute important comorbidities in COPD, with systemic inflammation proposed as a common mechanistic link. Fibrinogen has prognostic role in COPD. We aimed to determine whether aortic stiffness and quadriceps weakness are linked in COPD, and whether they are associated with the systemic inflammatory mediator-fibrinogen. Aortic pulse wave velocity (aPWV), quadriceps maximal volitional contraction (QMVC) force and fibrinogen were measured in 729 patients with stable, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages II-IV COPD. The cardiovascular and muscular manifestations exist independently (P=0.22, χ2). Fibrinogen was not associated with aPWV or QMVC (P=0.628 and P=0.621, respectively), making inflammation, as measured by plasma fibrinogen, an unlikely common aetiological factor.

Publication Date
2018-12
Online Publication Date
2018-04-04
Acceptance Date
2018-03-12
Keywords
copd pathology, Aged, Aorta, Cross-Sectional Studies, Female, Fibrinogen, Humans, Male, Middle Aged, Muscle Contraction, Muscle Weakness, Prospective Studies, Pulmonary Disease, Chronic Obstructive, Pulse Wave Analysis, Quadriceps Muscle, Vascular Stiffness
Journal Title
Thorax
Journal ISSN
0040-6376
1468-3296
Volume Title
73
Publisher
BMJ
Sponsorship
NIHR West Anglia Comprehensive Local Research Network (CLRN) (via Cambridge University Hospitals NHS Foundation Trust (CUH)) (RCF FUNDING 2013/14)
Technology Strategy Board (101024 TP 9157-61188)
British Heart Foundation (None)
British Heart Foundation (None)
British Heart Foundation (None)